The use of medicines in treating lipid disorders at Thuan Thao General Clinic in the first 6 months of 2024

Abstract

Dyslipidemia is one of the leading risks leading to dangerous cardiovascular
events. Timely detection and effective treatment will limit the risk of death caused by
cardiovascular diseases. Cross-sectional descriptive research method was conducted on
426 prescriptions of patients with lipid disorders at Thuan Thao General Clinic from
January 1, 2024 to June 30, 2024. The majority of patients are male with a rate of 54,23%.
The age group mainly from 55 - 69 years old accounts for the highest proportion with
67,37%. Triglyceride, total cholesterol and LDL-C indexes were mostly at borderline high
levels with 81,92%; 80,05% and 84,04% respectively, HDL-C indexes were all at normal
levels at all patients in the study sample. Most clinics use a treatment regimen of Statin
monotherapy, accounting for 96,00%; Atorvastatin is used the most with 92,25% mainly at
medium intensity, reaching 56,10%. Rosuvastatin only accounts for 3,76%. Fenofibrate
was used at a rate of 2,58%, and Statin + fibrate regimen at 1,41%. Dyslipidemia drugs are
usually combined with drugs to treat hypertension and diabetes. Patients are prescribed
groups of drugs that are on the Ministry of Health's list of recommended treatments for
lipid disorders